Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
MYC is an iconic oncogene that has been at the forefront of cancer research since its discovery. Looking back over the history of MYC research provides us with a framework with which to progress in the next 25 years, as outlined in this Timeline.
During the past century, the response to hypoxia has emerged as an important phenotypic determinant of a tumour, with repercussions for sensitivity to radiation and chemotherapy. This Timeline provides a historical overview of responses to hypoxia while looking forward to therapeutic strategies that are being developed to exploit them.
M. Judah Folkman is regarded by many as the father of research into the therapeutic targeting of angiogenesis. For cancer research, what were his most notable achievements?
One hundred years ago, Paul Ehrlich received the Nobel Prize for Physiology or Medicine. His idea of creating 'magic bullets' for use in the fight against human diseases has inspired generations of scientists to devise powerful molecular cancer therapeutics.
The Wnt signalling pathway has a crucial role in the development of all animal species, and mutations or deregulated expression of components of the Wnt pathway can result in cancer. This Timeline examines the past 25 years of crucial discoveries — from a variety of disciplines — about the components and functions of this pathway.
